{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:10:19Z","timestamp":1788379819205,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1124\/dmd.112.046060","type":"journal-article","created":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T16:23:57Z","timestamp":1342196637000},"page":"1945-1952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole"],"prefix":"10.1016","volume":"40","author":[{"given":"Mosun A.","family":"Ayan-Oshodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Annes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.112.046060_bib1","series-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","first-page":"1175","article-title":"Antimicrobial agents: antifungal agents","author":"Bennett","year":"1996"},{"key":"10.1124\/dmd.112.046060_bib2","first-page":"443","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective","volume":"43","author":"Bjornsson","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.046060_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.112.046060_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/21.5.633","article-title":"Pharmacokinetic study of the interaction between rifampicin and ketoconazole","volume":"21","author":"Doble","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.112.046060_bib5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.046060_bib6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/17425255.2010.516251","article-title":"Evaluation of models for predicting drug-drug interactions due to induction","volume":"6","author":"Fahmi","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.112.046060_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1056-8719(02)00168-5","article-title":"A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro","volume":"46","author":"Fayer","year":"2001","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.112.046060_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/187231209789352085","article-title":"Revisiting the metabolism of ketoconazole using accurate mass","volume":"3","author":"Fitch","year":"2009","journal-title":"Drug Metab Lett"},{"key":"10.1124\/dmd.112.046060_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0009-9236(98)90146-1","article-title":"The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin","volume":"64","author":"Gorski","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.046060_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.112.046060_bib11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0090-9556(24)15238-5","article-title":"The use of human hepatocyte cultures to study the induction of cytochrome P-450","volume":"27","author":"Kostrubsky","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.046060_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0026-895X(25)09118-7","article-title":"Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4","volume":"36","author":"Kronbach","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.112.046060_bib13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jps.10086","article-title":"Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs","volume":"91","author":"Kuroha","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.112.046060_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1749-6632.2001.tb03845.x","article-title":"Effect of flow configuration and membrane characteristics on membrane fouling in a novel multicoaxial hollow-fiber bioartificial liver","volume":"944","author":"MacDonald","year":"2001","journal-title":"Ann NY Acad Sci"},{"key":"10.1124\/dmd.112.046060_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/156802608783334088","article-title":"Recent progress in the medicinal chemistry of gamma-secretase inhibitors","volume":"8","author":"Olson","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.112.046060_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0076-6879(96)72044-X","article-title":"Use of human hepatocytes to study P450 gene induction","volume":"272","author":"Strom","year":"1996","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.112.046060_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.112.046060_bib18","series-title":"Metabolic Drug Interactions","first-page":"115","article-title":"CYP3A","author":"Wrighton","year":"2000"},{"key":"10.1124\/dmd.112.046060_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1124\/dmd.109.030841","article-title":"Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans","volume":"38","author":"Yi","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.112.046060_bib20","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1124\/dmd.107.016543","article-title":"Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine","volume":"35","author":"Zhang","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624061403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624061403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.112.046060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:45:59Z","timestamp":1739904359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624061403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0090955624061403"],"URL":"https:\/\/doi.org\/10.1124\/dmd.112.046060","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.112.046060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}